Loading company
NRX Pharmaceuticals, Inc.
NRXP · Nasdaq · ·
$2.92+1.4%Sep 29 close
- 1M
- -15.3%
- 6M
- +35.0%
- 1Y
- -12.7%
- 5Y
- -97.1%
NRXP · Nasdaq · ·
$2.92+1.4%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $1.1M | $0.00 | — |
| Profit | -$16.5M | -$17.6M | +6.03% |
| Profit per share | -$0.74 | -$0.15 | -393.33% |
| Free Cash Flow | -$3.5M | -$3.7M | +5.20% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
NRX Pharmaceuticals, Inc. has no earnings call transcript available.
“The second quarter of 2026 was a major inflection point for NRx as we advance our mission to bring hope to the most vulnerable patients battling depression and suicidal ideation,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
NRx Pharmaceuticals, Inc. ( www.nrxpharma.com ), is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. The Company is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA), and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression. Notice Regarding
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from NRX Pharmaceuticals, Inc.’s Item 2.02 8-K filed August 17, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.